Results 201 to 210 of about 12,173,418 (313)

Investigation on the therapeutic potential of the placebo effect open label

reservedIl presente elaborato indaga l’efficacia del placebo open label, trattamento attraverso il quale in modo consapevole e dichiarato vengono somministrati ai pazienti sostanze prive di principio attivo ma che producono comunque dei miglioramenti ...
ACCARDO, FRANCESCO LORENZO
core  

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-controlled Device Trials: Insights from REDUCE LAP-HF II. [PDF]

Circ Popul Health Outcomes
Girard AA, Mylavarapu U, Komtebedde J, Arnold SV, Solomon SD, Leon MB, Van Veldhuisen DJ, Cutlip DE, Cikes M, Zile MR, Gustafsson F, Lilly SM, Boyle A, Cleland JGF, Kaye DM, Emani S, Gupta DK, Hoendermis ES, Flaherty JD, Muller DW, Kapadia SR, Herrmann HC, Cohen DJ, Shah SJ, Spertus JA.   +24 more
europepmc   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Dose-extending placebo effect in a rat model of buprenorphine maintenance treatment. [PDF]

Psychopharmacology (Berl)
Pitts KM, Pilz EM, Colloca L, Shaham Y, Chow JJ.   +4 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Triadic relations in healthcare: surveying physicians' perspectives on generative AI integration and its role on empathy, the placebo effect and patient care. [PDF]

Front Psychol
Faria V, Goturi N, Dynak A, Talbert C, Pondelis N, Annoni M, Blease C, Holmes SA, Moulton EA.   +8 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Justice for Placebo: Placebo Effect in Clinical Trials and Everyday Practice. [PDF]

Medicines (Basel)
Knezevic NN, Sic A, Worobey S, Knezevic E.   +3 more
europepmc   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source